WorldWide Antimalarial Resistance Network
WWARN is a global collaboration working to ensure that anyone affected by malaria receives effective and safe drug treatment. WWARN will provide urgently needed, comprehensive, timely and quality-assured intelligence to track the emergence of malarial drug resistance. More about WWARN
Our modules
Clinical:
Clinical responses of malaria patients treated with various drugs Find out more
Pharmacology:
Precise antimalarial drug concentrations and pharmacokinetic parameters for key target populationsFind out more
in vitro:
In vitro drug susceptibility results from malaria parasites collected from infected patientsFind out more
Molecular:
Molecular markers for drug resistance in malaria parasitesFind out more
WWARN Explorer preview
Use this interactive tool to explore results from studies examining complementary aspects of antimalarial drug resistance: treatment outcomes and measures from clinical trials of drug efficacy; pharmacological profiles of antimalarial drugs across key target populations; in vitro assessment of drug susceptibility of parasite isolates; and molecular markers of parasite resistance. Find out more
Get involved
WWARN affiliated networks support and enhance capacity in malaria endemic countries. See how your research group could become involved.Find out more
Artemisinin resistance
Call for participants - Parasites with decreased sensitivity to artemisinin derivatives have been reported in Western Cambodia. Join the WWARN Artemisinin Resistance Marker Platform to accelerate the identification and validation of molecular markers of artemisinin resistance.Find out more
2010-07-13
A recent study investigating the antimalarial action of artemisinins found that mitochondrion are an important direct target. The full article is avalaible online in the peer-reviewed, open-access...Read the full story
- Choose a language:
